Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | MGLL | Q99685 | 3/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10636211 | 0.82 | EPHX2 (0.53) | KLK7EPHX1NAAAEPHX2MEN1 | |
| SCHEMBL16755635 | 0.81 | TDP1 (0.51) | KLK7EPHX1MGLLNAAAEPHX2 | |
| SCHEMBL25476011 | 0.79 | MAPT (0.48) | KLK7EPHX1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8107320 | 0.79 | SIGMAR1 (0.44) | KLK7EPHX2MEN1RAB9AKMT2A | |
| Phenylbutanoic Acid SCHEMBL10636202 | 0.78 | HDAC3 (0.64) | EPHX1EPHX2MEN1RAB9AKMT2A | |
| SCHEMBL6651781 | 0.77 | EPHX1 (0.58) | EPHX1EPHX2RAB9A | |
| SCHEMBL8116326 | 0.77 | SIGMAR1 (0.48) | KLK7EPHX1EPHX2MEN1RAB9A | |
| SCHEMBL16921289 | 0.76 | EPHX1 (0.49) | KLK7EPHX1NAAAEPHX2MEN1 | |
| SCHEMBL6049169 | 0.76 | SIGMAR1 (0.61) | EPHX1NAAAEPHX2MEN1KMT2A | |
| SCHEMBL11171348 | 0.75 | EPHX1 (0.56) | EPHX1EPHX2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180094029-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | ALCON RESEARCH, LTD. | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180094029-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | KLK7 2616/4885EPHX1 2710/4885MGLL 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.